Перспективы применения дорназы альфа в детской респираторной медицине
Аннотация
Перспективы применения дорназы альфа в детской респираторной медицине.
Об авторе
И. К. Волков
ГОУ ВПО "Первый Московский государственный медицинский университет им. И.М.Сеченова"
Россия
Россия
д. м. н., проф. кафедры детских болезней
119992, Москва, ул. Большая Пироговская, 19. Тел.: (499) 248-42-66.
Список литературы
1. Lucas A.M., Douglas L.C. Principles underlying ciliary activity in the respiratory tract. II. A comparison of nasal clearance in man, monkey and other mam-mals. Arch. Otolaryngol. 1934; 20: 518–541.
2. Sleigh M. Mucus propulsion. In: Crystal R.G., West J.B. et al., eds. The lung: scientific fundations. New York: Raven Press Ltd.; 1991; vol. 1: 189–197.
3. Nadel J.A. New approaches to regulation of fluid secretion in airways. Chest 1981; 80 (Suppl): 849–851.
4. Picot R., Das I., Reid L. Pus desoxyribonucleic acid and sputum viscosity. Thorax 1978; 33: 235–242.
5. Stutts M.J., Canessa C.M., Olsen J.C. et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995; 269: 847–850.
6. Lieberman J. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. J.A.M.A. 1968; 205: 312–313.
7. Shak S., Capon D.J., Hellmiss R. et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc. Nat. Acad. Sci. USA 1990; 87: 9188–9192.
8. Pinder J.C., Gratzer W.B. Investigation of the actin-deoxyribonuclease I interaction using a pyreneconjugated actin derivative. J. Biochem. (Tokyo) 1982; 21: 4886–4890.
9. Anselmo M.A.,Lands L.C. Cystic fibrosis. In: Pediatric respiratory medicine. St. Louis; 2008. Mosby; 845–907.
10. Matthews L.W., Spector S., Lemm J., Potter J.L. The overall chemical composition of pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy. Am. Rev. Respir. Dis. 1963; 88: 199–204.
11. Rozov T., de Oliveira V.Z., Santana M.A. et al. Dornase alfa improves the health-related quality of life among Brazilian patients with cystic fibrosis – a one-year prospective study. Pediatr. Pulmonol. 2010; 45 (9): 874–882.
12. Капpанов Н.И., Гембицкая Т.Е., Симонова О.И. и др. Опыт длительного применения нового муколитического препарата "Пульмозим" у больных муковисцидозом. Тер. арх. 2001; 1: 55–58.
13. Волков И.К. Возможности использования дорназы альфа (пульмозим) в детской пульмонологии. Пульмонология 2004; 4: 113–117.
14. Quan J.M., Tiddens H.A.W.M., Sy J.P. et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis and mild lung function abnormalities. J. Pediatr. 2001: 139: 813–820.
15. Liou T.G., Adler F.R., Fitz Simmons S.C. et al. Predictive 5-year survivorship model of cystic fibrosis. Am. J. Immunol. 2001; 153: 345–352.
16. Shah P.L., Conway S., Scott S.F. et al. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4 year period. Respiration 2001; 68: 160–164.
17. Hodson M.E., McKenzie S., Harms H.K. et al. Dornase alfa in the treatment of cystic fibrosis in Europe: a report from the epidemiologic registry of cystic fibrosis. Pediatr. Pulmonol. 2003; 36 (5): 427–432.
18. Hodson M.E., Shah P.L. Dnase trials in cystic fibrosis. Eur. Respir. J. 1995; 8: 1786–1791.
19. Fuchs H.J., Borowitz D.S., Christiansen D.H. et al. Effect of aerosolized recombinant human Dnase on exacerbations of respiratory symptoms and on pulmonary functions in patients whit cystic fibrosis: the Pulmozyme study group. N. Engl. J. Med. 1994; 331: 637–642.
20. Mainz J.G., Schiller I., Ritschel C. et al. Sinonasal inhalation of dornase alfa in CF: A double-blind placebo-controlled crossover pilot trial. Auris Nasus Larynx 2011; 38 (2): 220–227.
21. Dentice R., Elkins M. Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database Syst. Rev. 2011; 5: CD007923.
22. Jones A.P., Wallis C.E. Dornase alpha for cystic fibrosis. Cochrane Database Syst. Rev. 2010; 3:CD001127.
23. Kristensen K. Recombinant human DNase in conditions other than cystic fibrosis. Ugeskr. Laeg. 2010; 172 (8): 616–619.
24. Волков И.К., Давыдова И.В., Куличихин В.Г. и др. Эффективность дорназы альфа (пульмозим) у детей с хроническими заболеваниями легких. Пульмонология 2003; 3: 79–82.
25. Puchelle E., Zahm J.M., de Bentzmann S. et al. Effects of rhDNase on purulent airway secretions in chronic bronchitis. Eur. Respir. J. 1996; 9 (4): 765–769.
26. Berge M., Brinkhorst G., Kroon A.A., Jongste J.C. DNase treatment in primary ciliary dyskinesia-assessment by nocturnal pulse oximetry. Pediatr. Pulmonol. 1999; 27: 59–61.
27. Merkus P.J., de Hoog M., van Gent R., de Jongste J.C. DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis. Eur. Respir. J. 2001; 18 (4): 734–737.
28. Nasr S.Z., Strouse P.J., Soskolne E. et al. Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis. Chest 2001; 120: 203–208.
29. Kupeli S., Teksam O, Dogru D., Yurdakok M. Use of recombinant human DNase in a premature infant with recurrent atelectasis. Pediatr. Intern. 2003; 45: 584–586.
30. El Hassan N.O., Chess P.R., Huysman M. et al. Rescue use of DNase in critical lung atelectasis and mucus retention in premature neonates. Pediatrics 2001; 108: 468–471.
31. Hendriks T., de Hoog M., Lequin M.H. et al. DNase and atelectasis in non-cystic fibrosis pediatric patients. Crit. Care 2005; 9 (4): R35–R356.
32. Durward A., Forte V., Shemie S.D. Resolution of mucus plugging and atelectasis after intratracheal rhDNase therapy in a mechanically ventilated child with refractory status asthmaticus. Crit. Care Med. 2000; 28 (2): 560–562.
33. Manna S.S., Shaw J., Tibby S.M. A Durward treatment of plastic bronchitis in acute chest syndrome of sickle cell disease with intratracheal rhDNase. Arch. Dis. Child. 2003; 88: 626–627.
34. Scherer T., Geller D.E., Owyang L. et al. A technical feasibility study of dornase alfa delivery with eFlow® vibrating membrane nebulizers: aerosol characteristics and physicochemical stability. J. Pharm. Sci. 2011; 100 (1): 98–109.
35. Bush A. Bronchoscopy in paediatric intensive care. Paediatr. Respir. Rev. 2003: 4 (1): 67–73.
36. Slattery D.M., Waltz D.A., Denham B. et al. Bronchoscopically administered recombinant human DNase for lobar atelectasis in cystic fibrosis. Pediatr. Pulmonol. 2001; 31 (5): 383–388.
37. Simpson G., Roomes D., Reeves B. Successful treatment of empyema thoracis with human recombinant deoxyribonuclease. Thorax 2003; 58: 363–366.
38. Conway S.P. Evidence-based medicine in cystic fibrosis: how should practice change? Pediatr. Pulmonol. 2002; 34: 242–247.
39. Капранов Н.И., Воронкова А.Ю., Шабалова Л.А. и др. Клиническое значение рекомбинантной человеческой ДНКазы (Пульмозим) в комплексной терапии больных муковисцидозом. Рос. педиатр. журн. 2001; 3: 26–31.
40. McKenzie S.G., Chowdhury S., Strandvik B., Hodson M.E. Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis. Pediatr. Pulmonol. 2007; 42 (10): 928–937.
Для цитирования:
Волков И.К. Перспективы применения дорназы альфа в детской респираторной медицине. Пульмонология. 2011;(5):97-102. https://doi.org/10.18093/0869-0189-2011-0-5-97-102
For citation:
Volkov I.K. Perspectives for treatment with dornase-alfa in paediatric respiratory medicine. Russian Pulmonology. 2011;(5):97-102. (In Russ.) https://doi.org/10.18093/0869-0189-2011-0-5-97-102
Просмотров: 260
Послать статью по эл. почте 